Abcellera Biologics Inc (ABCL) stock news · rev $12.4M
Abcellera Biologics Inc (ABCL) is a biotechnology company listed on US.
This ABCL news page leads with what Abcellera Biologics Inc filed — not a scraped headline mill.
No cached 8-K sentence for ABCL yet. We will not pad this page with generic market recap.
Latest reported ABCL revenue for 2026-06-30 was $12.4M. Net income was -$98.6M. Revenue was up 48.7% from 2026-03-31 to 2026-06-30. ABCL currently screens at market cap $1.12B.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the ABCL stock page; for the tape open the quote page.
Not investment advice.